Laryngeal cancer is a prevalent malignancy of the head and neck with a high rate of mortality. Corilagin, a natural gallic acid derivative, was isolated from PhmLlanthi Fructus, a “drug homologous food”, and its in vitro and in vivo activity were investigated. Results of our study demonstrate that corilagin has significant anti-laryngeal cancer activity in vitro and in vivo. It was observed that corilagin inhibits proliferation and migration of cancerous laryngeal cells Hep-2 and TU212 in a concentration-dependent manner and inhibits growth of transplanted tumors in nude mice without apparent signs of toxicity. The anti-cancer effects of corilagin may be attributed to the inhibition of human laryngeal cancer proliferation by activation of mitochondrial apoptotic and endoplasmic reticulum stress signaling pathways and inhibition of Akt and STAT3 pathways.

喉癌是一种常见的头颈部恶性肿瘤，死亡率很高。从“药物同源食品” PhmLlanthi Fructus中分离出一种天然的没食子酸衍生物Corilagin，并对其体外和体内活性进行了研究。我们的研究结果表明，柯里拉京有显著的抗喉癌活动在体外和体内。观察到胶原蛋白以浓度依赖的方式抑制癌性喉癌细胞Hep-2和TU212的增殖和迁移，并且抑制裸鼠中移植的肿瘤的生长，而没有明显的毒性迹象。Corilagin的抗癌作用可能归因于通过激活线粒体凋亡和内质网应激信号通路以及抑制Akt和STAT3通路来抑制人喉癌的增殖。